See also this year's filing and all EDGAR filings for this company.
PDF Report 0001621443_2020_Zynerba_Pharmaceuticals_Inc.pdf
Logs
| warning | The stock price does not exist | industry.us_generic | {} |
| info | NetIncome node detected by revenue/expenses heuristic | input.sec.calculation_linkbase.edgar_model_mapping | {'net_inc_node': 'OperatingIncomeLoss'} |
Graph
Absolute values for 0001621443, Zynerba Pharmaceuticals Inc
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 87,056,023 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 362,724 |
| 3 | remainder_Assets | 345,849 |
| 4 | LiabilitiesCurrent | 12,058,164 |
| 5 | LiabilitiesNoncurrent | 109,689 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 14,472,509 |
| 9 | ResearchAndDevelopmentExpense | 10,406,983 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 30,267 |
| 12 | remainder_NetIncome | 121,519 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 87,764,596 |
| 1 | Liabilities | 12,167,853 |
| 2 | Expenses | 24,879,492 |
| 3 | Revenues | 30,267 |
| 4 | StockholdersEquity | 75,596,743 |
| 5 | NetIncome | -24,727,706 |
| 6 | ComprehensiveNetIncome | -24,727,706 |
| 7 | BaseVar | 62,481,864 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 2.80 |
| 9 | EconomicCapitalRatio | 3.56 |
Edgar->Model Mapping
Feature Distribution
Change over Time
